[1] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 2013, 381: 468-475.
[2] Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval. Hepatology, 2017, 66: 1296-1313.
[3] Nguyen K, Pan C, Xia V, et al. Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients. J Viral Hepat, 2015, 22: 809-816.
[4] Li J, Zhang TY, Song L W, et al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol Res, 2018, 48: E133-e145.
[5] Liu T, Yao M, Liu S, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget, 2017, 8: 16498-16506.
[6] Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: Experimental data and literature review. Clin Rev Allergy Immunol, 2018, 54: 282-294.
[7] Yao M, Wang L, You H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta, 2019.
[8] Wei M, Xu Z, Pan X, et al. Serum GP73-An additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT. Sci Rep, 2019, 9: 1170.
[9] Lu FM, Zhang Y. Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis. Chinese Journal of Hepatology, 2018, 26: 321-324.
[10] Liu L, Wang J, Feng J, et al. Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease. Sci Rep, 2018, 8: 16730.
[11] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016, 65: 700-710.
[12] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol, 2017.
[13] Lu F, Wang J, Chen X, et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med, 2017, 11: 502-508.
[14] Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther, 2018.
[15] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individual. J Clin Virol, 2018, 99-100: 71-78.
[16] Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol, 2018, 68: 847-849.
[17] Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol, 2017, 66: 275-281.
[18] Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med, 2017, 9.
[19] Li X, Zhang J, Yang Z, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol, 2014, 60: 975-984.
[20] Liu Y, Zeng W, Xi J, et al. Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition. J Hepatol, 2019, 70: 557-559.
[21] Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int, 2017, 37: 995-1001. |
